---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257684"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-06-04T21:00:25+00:00"
generated_at: "2026-06-04T21:16:48.368456+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics CFO resigns, appoints new CFO and two independent directors

## Summary
- CFO Nicholas Maestas resigns effective June 5, 2026; Justin Trojanowski named VP Finance, Principal Financial Officer and Corporate Secretary.
- Board appoints Drake Richey and John Yee, MD, MPH as Class II independent directors effective June 4, 2026.
- Company received Nasdaq non-compliance notice on May 22 due to board vacancies; believes it can cure with one remaining vacancy.
- Amended director compensation policy reduces annual cash retainers: base $20K, committee chair $5K-$10K, member $2.5K-$5K.

## SEC filing metadata
- accession: 0001193125-26-257684
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-06-04T21:00:25+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/d91703d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257684
- JSON: https://secwatch.observer/filing/0001193125-26-257684.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257684.txt

## Key facts
- Executive change
  John David Yee was appointed as Class II Director at Tempest Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm
- Executive change
  Justin Trojanowski was appointed as Vice President, Finance, Principal Financial Officer and Corporate Secretary at Tempest Therapeutics, Inc..
  - Action: appointed
  - Role: Vice President, Finance, Principal Financial Officer and Corporate Secretary
  source text: the Board of Directors of the Company (the “Board”) appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm
- Executive change
  William Drake Richey was appointed as Class II Director at Tempest Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: the Board appointed Dr. John David Yee and Mr. William Drake Richey as Class II directors to fill vacancies on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm
- Executive change
  Nicholas Maestas resigned as Chief Financial Officer at Tempest Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.